Vor Biopharma

Company snapshot

Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and commercialization to address serious autoantibody-driven conditions worldwide.

• 6 active pipeline program(s) linked via ClinicalTrials.gov.
• 12 US patent(s) indexed to this assignee profile.
• 6 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Vor Biopharma. Not investment advice.

• Congress May 18, 2026
  Global Pharma Tech
• Presentation
  ABCD-123 Phase 3 interim analysis in obesity

Recent activity

Latest pipeline, patent, and corporate events for Vor Biopharma.

1. Jun 8, 2026 Clinical update

   RC18G006 — Phase 3

2. Jun 8, 2026 Clinical update

   Telitacicept — Phase 3

3. Jun 5, 2026 Clinical update

   Telitacicept — Phase 3

4. Jun 5, 2026 Clinical update

   Telitacicept — Phase 3

5. May 23, 2026 Clinical update

   VCAR33 — Phase 2

View all clinical trial activity →

• What is Vor Biopharma?

  Vor Biopharma is a biotech organization headquartered in Cambridge, USA. It trades on NYSE under ticker VOR. Primary therapeutic focus areas include Generalized Myasthenia Gravis, Leukemia, Myeloid, Acute, Systemic Lupus Erythematosus, Primary Sjogren's Disease. NovaPharmaNews li

• Is Vor Biopharma publicly traded?

  Yes. Vor Biopharma is listed with ticker VOR on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Vor Biopharma develop or market?

  We link 4 drug profile(s) where Vor Biopharma is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/vor-biopharma#company-drugs.

• What are the latest developments for Vor Biopharma?

  In the last 12 months our linked public records show 6 trial program update(s) and 1 US patent grant(s) tied to this profile.

• What therapeutic areas does Vor Biopharma focus on?

  Vor Biopharma focuses on Generalized Myasthenia Gravis, Leukemia, Myeloid, Acute, Systemic Lupus Erythematosus based on our analysis of their pipeline programs and drug development activities.